FOLH1 and neoplasm: Baseline imaging biomarkers on PSMA-PET/CT, such as mean standardised uptake value (SUVmean), PSMA-avid total tumour volume, and inter-lesional PSMA heterogeneity, have shown promise in predicting treatment response and assessing outcomes.